Sutureless aortic valves, the alternative to traditional and transcatheter valves.
The concept is a prosthetic valve comprising a bovine pericardium tissue valve attached to a self-expandable anchoring device, which has the dual role of supporting the valve and providing fixation to the implantation site.
Sutureless biological valves were designed to simplify and significantly accelerate the surgical replacement of a diseased valve and first require complete excision of the calcified native valve.
Shortening the time required for aortic valve replacement may help to reduce morbidity and mortality, especially in patients who require complex multivalve or combined valve and coronary procedures. Transcatheter aortic valve implantation (TAVI) may eliminate the need for open heart surgery in select groups of patients. In the USA, there has been an FDA-approved percutaneously implantable aortic valve system for high surgical risk and inoperable patients with symptomatic aortic stenosis with other catheter-based devices on trial use since October 2012.